International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today that it had launched the first phase of its previously
announced joint marketing campaign with John Mauldin, the founder and
Chairman of Millennium Wave Investments, to market Lifeline Skin Care's
(LSC) new topical skin care products to more than one million of
Mauldin's subscribers. This launch follows ISCO's earlier successful
release to its own investor base and to the general public through its
website, http://www.lifelineskincare.com.
Mauldin, a best-selling writer, author of a monthly investment
newsletter, and recognized marketing expert, provides LSC with the
skills and a platform to enable LSC to continue expanding its sales
while keeping marketing cost per customer lower than would be possible
with a traditional media campaign.
Lifeline Skin Care's exclusive patent pending skin rejuvenation serums
contain extracts from ISCO's proprietary "parthenogenetic" stem cells
created from unfertilized eggs. The stem cell extract was discovered
during ISCO's therapeutic research that revealed the extract's potential
applications in skin cell rejuvenation. Independent third party testing
indicates that both the day and the night serums now being offered have
significant positive effects on the look and feel of the skin.
"Having seen a strong demand from our investors and followers, we have
been working diligently to increase both our marketing and production
capabilities. John Mauldin's participation will support the continuation
of our rapid progress," says Dr. Ruslan Semechkin, CEO of Lifeline Skin
Care.
John Mauldin adds, "I'm pleased to be involved with LSC and to help
these truly revolutionary skin care products reach a broader audience.
This new collaboration gives me the ability to offer these unique LSC
products to my loyal client base."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). These proprietary cells
avoid ethical issues associated with use or destruction of viable human
embryos and, unlike most other major stem cell types, can be immune
matched and be a source of therapeutic cells with minimal rejection
after transplantation into hundreds of millions of individuals of
differing racial groups. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary, Lifeline Cell Technology, and has developed and is now
marketing a line of skin care products via its subsidiary, Lifeline Skin
Care. ISCO is advancing novel human stem cell-based therapies where
cells have been proven to be efficacious but traditional small molecule
and protein therapeutics have not. More information is available on
ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, product introduction
plans and related support, the potential benefits of planned products,
anticipated sales growth for recently introduced products, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care,
anti-aging
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline
Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice
President, ISCO
ras@intlstemcell.com |
